Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
21.48
-1.00 (-4.43%)
At close: Nov 4, 2024, 4:00 PM
20.40
-1.08 (-5.03%)
After-hours: Nov 4, 2024, 4:37 PM EST
KNSA Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Revenue | 384.1 | 270.26 | 220.18 | 38.54 | - | - | |
Revenue Growth (YoY) | 54.41% | 22.74% | 471.24% | - | - | - | |
Cost of Revenue | 149.66 | 89.93 | 46.97 | 9.94 | - | - | |
Gross Profit | 234.44 | 180.33 | 173.21 | 28.61 | - | - | |
Selling, General & Admin | 164.22 | 129.43 | 97.95 | 85.95 | 45.32 | 34.96 | |
Research & Development | 96.46 | 76.1 | 65.49 | 99.3 | 112.04 | 135 | |
Operating Expenses | 260.68 | 205.52 | 163.44 | 185.25 | 157.36 | 169.96 | |
Operating Income | -26.24 | -25.2 | 9.77 | -156.64 | -157.36 | -169.96 | |
Interest & Investment Income | - | - | - | - | - | 6.05 | |
Other Non Operating Income (Expenses) | 9.51 | 8.54 | 1.25 | 0.1 | 1.13 | - | |
Pretax Income | -16.72 | -16.65 | 11.03 | -156.54 | -156.23 | -163.91 | |
Income Tax Expense | -7.66 | -30.74 | -172.34 | 1.39 | 5.15 | -2.05 | |
Net Income | -9.07 | 14.08 | 183.36 | -157.92 | -161.38 | -161.87 | |
Net Income to Common | -9.07 | 14.08 | 183.36 | -157.92 | -161.38 | -161.87 | |
Net Income Growth | - | -92.32% | - | - | - | - | |
Shares Outstanding (Basic) | 71 | 70 | 69 | 69 | 62 | 54 | |
Shares Outstanding (Diluted) | 71 | 72 | 70 | 69 | 62 | 54 | |
Shares Change (YoY) | 1.53% | 2.13% | 2.69% | 10.89% | 14.42% | 82.92% | |
EPS (Basic) | -0.13 | 0.20 | 2.64 | -2.30 | -2.61 | -2.99 | |
EPS (Diluted) | -0.13 | 0.20 | 2.60 | -2.30 | -2.61 | -2.99 | |
EPS Growth | - | -92.31% | - | - | - | - | |
Free Cash Flow | 11.1 | 13.17 | 5.7 | -126.71 | -136.82 | -161.57 | |
Free Cash Flow Per Share | 0.16 | 0.18 | 0.08 | -1.85 | -2.21 | -2.99 | |
Gross Margin | 61.04% | 66.72% | 78.67% | 74.22% | - | - | |
Operating Margin | -6.83% | -9.32% | 4.44% | -406.38% | - | - | |
Profit Margin | -2.36% | 5.21% | 83.28% | -409.72% | - | - | |
Free Cash Flow Margin | 2.89% | 4.87% | 2.59% | -328.75% | - | - | |
EBITDA | -24.4 | -22.86 | 12.18 | -154.28 | -154.96 | -167.9 | |
EBITDA Margin | -6.35% | -8.46% | 5.53% | - | - | - | |
D&A For EBITDA | 1.84 | 2.34 | 2.4 | 2.36 | 2.41 | 2.07 | |
EBIT | -26.24 | -25.2 | 9.77 | -156.64 | -157.36 | -169.96 | |
EBIT Margin | -6.83% | -9.32% | 4.44% | - | - | - | |
Revenue as Reported | 384.1 | 270.26 | 220.18 | 38.54 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.